Summit Therapeutics (SMMT) Short term Debt: 2016-2020
Historic Short term Debt for Summit Therapeutics (SMMT) over the last 4 years, with Mar 2020 value amounting to -$13.0 million.
- Summit Therapeutics' Short term Debt was N/A to -$13.0 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$13.0 million, marking a year-over-year change of. This contributed to the annual value of $105,000 for FY2019, which is N/A change from last year.
- Per Summit Therapeutics' latest filing, its Short term Debt stood at -$13.0 million for Q1 2020, which was down 12,496.25% from $105,000 recorded in Q4 2019.
- Summit Therapeutics' Short term Debt's 5-year high stood at $105,000 during Q4 2019, with a 5-year trough of -$16.7 million in Q2 2018.
- Over the past 3 years, Summit Therapeutics' median Short term Debt value was -$8.9 million (recorded in 2018), while the average stood at -$9.3 million.
- In the last 5 years, Summit Therapeutics' Short term Debt rose by 10.83% in 2017 and then plummeted by 318.88% in 2018.
- Over the past 5 years, Summit Therapeutics' Short term Debt (Quarterly) stood at -$4.1 million in 2016, then decreased by 26.55% to -$5.2 million in 2017, then plummeted by 33.92% to -$6.9 million in 2018, then fell by 29.55% to $105,000 in 2019, then reached -$13.0 million in 2020.
- Its Short term Debt was -$13.0 million in Q1 2020, compared to $105,000 in Q4 2019 and -$8.9 million in Q4 2019.